All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the EHA 2022 Congress, the AML Hub spoke with Gert Ossenkoppele, VU University Medical Center, Amsterdam, NL. We asked, Does 10-day decitabine improve post-transplant outcomes in older patients compared with 3+7 chemotherapy?
Does 10-day decitabine improve post-transplant outcomes in older patients compared with 3+7 chemo?
Ossenkoppele begins by introducing the study presented at the congress, outlining the study design and trial results. He then highlights the overall survival, and feasibility of this therapy as a bridge to allogeneic transplant. At the EHA 2022 Congress, Ossenkoppele received the Jean Bernard Lifetime Achievement Award, for his outstanding contribution to the advancement of hematology.
Visual abstract | QuANTUM-First trial of quizartinib with standard chemotherapy and as continuation therapy in newly diagnosed FLT3-ITD+ AML
The AML Hub is happy to present a Visual Abstract summarizing key data from the phase III QuANTUM-First...
1st NCRI AML academy meeting | Advances in intensive chemotherapy for patients with AML
We spoke to Prof Gert Ossenkoppele at the 1st NCRI AML academy meeting about recent intensive chemotherapy advances for the treatment of patients with AML (acute...
Subscribe to get the best content related to AML delivered to your inbox